World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
52881
World Ranking
15839
National Ranking
7969

Paul B. Chapman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Paul B. Chapman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 308 publications — 18th percentile

18% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Paul B. Chapman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Paul B. Chapman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Paul B. Chapman is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily lies at the intersection of medicine and biochemistry, genetics, and molecular biology, with a strong focus on oncology, molecular biology, immunology, genetics, and cancer research.

Their scientific work revolves around several key topics including CAR-T cell therapy research, cancer immunotherapy and biomarkers, melanoma and MAPK pathways, immunotherapy and immune responses, cutaneous melanoma detection and management, cancer genomics and diagnostics, and microscopic colitis.

Paul B. Chapman has published multiple papers in various high-impact venues. Notable recent publications include:

  • Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade (2020, Journal of Clinical Oncology)
  • The State of Melanoma: Emergent Challenges and Opportunities (2021, Clinical Cancer Research)
  • LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade (2021, Science Translational Medicine)
  • Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials (2020, European Journal of Cancer)
  • Immune Checkpoint Inhibitor-Associated Optic Neuritis (2020, Ophthalmology)

The venues where Paul B. Chapman's work frequently appears highlight their focus on clinical oncology and cancer research. These include:

  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • Melanoma Research
  • Gastroenterology

Collaboration forms a significant part of their research activities. Frequent co-authors with whom Paul B. Chapman has worked include:

  • Alexander N. Shoushtari
  • Jedd D. Wolchok
  • Michael A. Postow
  • Margaret K. Callahan
  • Parisa Momtaz

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Inhibition of mutated, activated BRAF in metastatic melanoma.

    Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

  • Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

    Héctor Peinado;Maša Alečković;Simon Lavotshkin;Irina Matei

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

    Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang

  • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

    Ravid Straussman;Teppei Morikawa;Kevin Shee;Michal Barzily-Rokni

  • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

    Poulikos I. Poulikakos;Yogindra Persaud;Manickam Janakiraman;Xiangju Kong

  • Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

    Troy Z. Horvat;Nelly G. Adel;Thu-Oanh Dang;Parisa Momtaz

  • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

    Fei Su;Amaya Viros;Carla Milagre;Kerstin Trunzer

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

    Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford

  • KIT as a therapeutic target in metastatic melanoma

    Richard D. Carvajal;Cristina R. Antonescu;Jedd D. Wolchok;Paul B. Chapman

  • Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

    Paul B. Chapman;Lawrence H. Einhorn;Michael L. Meyers;Scott Saxman

  • Evolutionary dynamics of cancer in response to targeted combination therapy

    Ivana Bozic;Johannes G Reiter;Benjamin Allen;Benjamin Allen;Tibor Antal

  • Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

    Jennifer L. McQuade;Carrie R. Daniel;Kenneth R. Hess;Carmen Mak

  • The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

    Eric W. Joseph;Christine A. Pratilas;Poulikos I. Poulikakos;Madhavi Tadi

  • Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival

    Geoffrey Y. Ku;Jianda Yuan;David B. Page;Sebastian E. A. Schroeder

  • Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial

    Richard D. Carvajal;Jeffrey A. Sosman;Jorge Fernando Quevedo;Mohammed M. Milhem

  • Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells

    Dianna Y. Wu;Neil H. Segal;Stephane Sidobre;Mitchell Kronenberg

  • Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications

    Y.B. Su;Sejean Sohn;Susan E. Krown;Philip O. Livingston

Frequent Co-Authors

Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center
Katherine S. Panageas
Katherine S. Panageas Memorial Sloan Kettering Cancer Center
Richard D. Carvajal
Richard D. Carvajal Columbia University
Keith T. Flaherty
Keith T. Flaherty Harvard University
Alan N. Houghton
Alan N. Houghton Memorial Sloan Kettering Cancer Center
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Antoni Ribas
Antoni Ribas University of California, Los Angeles
David B. Solit
David B. Solit Memorial Sloan Kettering Cancer Center
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in healthcare goes beyond pursuing an MD. Many students look for alternative pathways and flexible online degree options to quickly enter the medical field. For example, online BSN programs for non nurses offer a fast-track route for those with a bachelor’s degree in another field to become registered nurses without starting over.

Not all nursing programs require the TEAS or HESI entrance exams—a big relief for some applicants. You can find nursing schools that don't require teas test, making the admission process smoother and less stressful.

For those interested in administrative roles, accelerated healthcare programs enable you to earn a healthcare administration degree online in less time than traditional options.

Additionally, coding and billing specialists are in high demand. For affordable entry, explore financial aid for medical billing and coding online classes. These programs offer quick certification and job-ready skills, making them a practical choice for career changers.

Best Scientists Citing Paul B. Chapman

Trending Scientists